Financial data tables

Moderna (MRNA) figures from its financial statements (company filings via Financial Modeling Prep), in US dollars; non-US reporters are converted to US dollars. Periods carry the company's own fiscal quarter and year, as its filings name them, with the date each period ended. Source filings are on the Filings tab.

Moderna quarterly results
PeriodRevenueGross profitOperating incomeNet incomeDiluted EPSGross marginOperating margin
Q3 FY2026 (ended Sep 30, 2026)$1.31B$995.0M$130.0M$162.0M$0.3875.8%9.9%
Q2 FY2026 (ended Jun 30, 2026)$145.0M$52.0M-$815.0M-$782.0M-$1.9735.9%-562.1%
Q1 FY2026 (ended Mar 31, 2026)$389.0M-$566.0M-$1.39B-$1.34B-$3.40-145.5%-356.8%
Q4 FY2025 (ended Dec 31, 2025)$678.0M$226.0M-$857.0M-$826.0M-$2.1133.3%-126.4%
Q3 FY2025 (ended Sep 30, 2025)$1.02B$8.0M-$260.0M-$200.0M-$0.510.8%-25.6%
Q2 FY2025 (ended Jun 30, 2025)$142.0M$23.0M-$907.0M-$825.0M-$2.1316.2%-638.7%
Q1 FY2025 (ended Mar 31, 2025)$107.0M$17.0M-$1.05B-$971.0M-$2.5215.9%-981.3%
Q4 FY2024 (ended Dec 31, 2024)$956.0M$217.0M-$1.25B-$1.12B-$2.9122.7%-130.3%
Moderna quarterly cash flow
PeriodOperating cash flowCapital expendituresFree cash flowShare repurchasesDividends paid
Q3 FY2026 (ended Sep 30, 2026)-$1.56B$47.0M-$1.61B$0.0M$0.0M
Q2 FY2026 (ended Jun 30, 2026)-$526.0M$37.0M-$563.0M$2.0M$0.0M
Q1 FY2026 (ended Mar 31, 2026)-$630.0M$62.0M-$692.0M$0.0M$0.0M
Q4 FY2025 (ended Dec 31, 2025)$930.0M$39.0M$891.0M$0.0M$0.0M
Q3 FY2025 (ended Sep 30, 2025)-$847.0M$33.0M-$880.0M$0.0M$0.0M
Q2 FY2025 (ended Jun 30, 2025)-$919.0M$3.0M-$922.0M$0.0M$0.0M
Q1 FY2025 (ended Mar 31, 2025)-$1.04B$117.0M-$1.15B$0.0M$0.0M
Q4 FY2024 (ended Dec 31, 2024)$825.0M$522.0M$303.0M$0.0M$0.0M
Moderna balance sheet
PeriodTotal assetsCash and equivalentsShort-term investmentsTotal debtTotal equity
Q3 FY2026 (ended Sep 30, 2026)$13.47B$1.20B$3.98B$4.18B$6.84B
Q2 FY2026 (ended Jun 30, 2026)$10.96B$1.72B$3.42B$1.29B$6.76B
Q1 FY2026 (ended Mar 31, 2026)$11.49B$1.91B$3.30B$1.30B$7.41B
Q4 FY2025 (ended Dec 31, 2025)$12.34B$2.60B$3.20B$1.30B$8.65B
Moderna revenue by segment
SegmentQ2 FY2026 (ended Jun 30, 2026)Q1 FY2026 (ended Mar 31, 2026)Q2 FY2025 (ended Jun 30, 2025)Q1 FY2025 (ended Mar 31, 2025)
Product Sales$171.0M$352.0M$176.0M$105.0M
Moderna revenue by region
RegionQ2 FY2026 (ended Jun 30, 2026)Q1 FY2026 (ended Mar 31, 2026)Q4 FY2025 (ended Dec 31, 2025)Q3 FY2025 (ended Sep 30, 2025)
United States$70.0M$73.0M$298.0M$782.0M
Europe$16.0M$239.0M$37.0M$16.0M
Rest Of The World$8.0M$40.0M$347.0M$175.0M
Moderna employees
YearEmployees
20254,700
20245,800
20235,600
20223,900
20212,700
20201,300

Moderna (MRNA) reported revenue of $1.31B in Q3 2026.

Ask Sterling

Register for a premium account to gain access to Sterling AI.

Get Started

Things you can ask Sterling:

Summarize Tesla's latest earnings reportWhy did NVIDIA's margins expand?Compare Apple vs Microsoft's cash flowWhat's driving EV industry growth?
Menu
Favorites